Other small molecule inhibitors of mevalonate pathway targeting farnesyl diphosphate synthase (FPPS) and geranylgeranyl diphosphate synthase (GGPPS) like the nitrogen-containing bisphosphonates (N-BPs) and their analogues have been studied in the setting of lytic bone disease and cancer (53, 54). The gene discussed is GGPS1; the disease is cancer.